Future Directions in Bladder Cancer Treatment: The Experts Weigh

Access Activity

Overview / Abstract:

Target Audience
Urology community physicians, physician assistants, nurse practitioners, nurses, and pharmacists.

Statement of Need/Program Overview
Immunotherapies are revolutionizing many cancer treatment regimens and show promise in locally advanced or metastatic bladder cancer. Immune checkpoint inhibitors are attempting to fill an unmet need in relapsed disease and biomarkers may assist in identifying patients most likely to respond. Though trial data are still evolving, mounting evidence suggests a role for immunotherapy earlier in the disease spectrum, as front-line therapy for cisplatin-ineligible patients, and in combinatorial regimens in late-stage disease. Join Drs. Neal Shore, Andrea Apolo, and Arjun Balar for this online on-demand activity as they dive into the latest data in bladder cancer therapies.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Monitor and review ongoing advanced bladder cancer trials with real time discussion of evidence-based data about new therapies.


Oct 23, 2021


Physician CME



Credits / Hours




Presenters / Authors / Faculty

Neal Shore, MD, FACS (Activity Chair)
Andrea B. Apolo
Arjun V. Balar, MD

Sponsors / Supporters / Grant Providers

AstraZeneca and Genentech

Keywords / Search Terms

Relias LLC Relias, Free CME, Bladder Cancer Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map